Understanding how a common lung cancer mutation triggers immune responses
Defining features of the neoantigen-specific T cell response against a common EGFR mutation in lung cancer
['FUNDING_FELLOWSHIP'] · CASE WESTERN RESERVE UNIVERSITY · NIH-10995102
This study is looking at how a specific change in the EGFR gene, common in lung cancer, can help the immune system recognize and fight cancer cells, which could lead to new treatments for lung cancer patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CASE WESTERN RESERVE UNIVERSITY (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10995102 on ClinicalTrials.gov |
What this research studies
This research investigates how the L858R mutation in the EGFR gene, which is prevalent in lung cancer, can stimulate the immune system to attack cancer cells. By analyzing the interaction between mutation-derived peptides and T cells, the study aims to uncover the mechanisms that enable the immune system to recognize and respond to this specific mutation. The approach includes characterizing the binding of these peptides to HLA complexes and assessing their ability to activate CD8+ T cells. This could lead to insights into developing targeted immunotherapies for lung cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients who have been diagnosed with the EGFR L858R mutation.
Not a fit: Patients without the EGFR L858R mutation or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the development of personalized immunotherapies for lung cancer patients with the EGFR L858R mutation.
How similar studies have performed: Previous research has shown promising results in targeting neoantigens for cancer immunotherapy, indicating that this approach has potential for success.
Where this research is happening
CLEVELAND, UNITED STATES
- CASE WESTERN RESERVE UNIVERSITY — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, STEPHEN LEE — CASE WESTERN RESERVE UNIVERSITY
- Study coordinator: WANG, STEPHEN LEE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.